CALA News and Press, Calithera Biosciences Inc. From 03/01/23

Nasdaq said Wednesday it will delist shares of Waitr ( OTCQB:ASAP ), Calithera Biosciences ( OTC:CALA ), Statera Biopharma ( OTCPK:STAB ), Allied Healthcare Products ( OTC:AHPI ) and Tricida ( OTCPK:TCDAQ ). The exchange will also delist Eqonex ( OTCPK:EQOSQ ), Sco...

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), today announced that its Board of Directors has determined, after extensive consideration of potential strategic alternatives, that it is in the best interests of its shareholders to dissolv...

Calithera Biosciences, Inc. (CALA) Q3 2022 Earnings Conference Call November 14, 2022, 17:00 ET Company Participants Stephanie Wong - CFO & Secretary Susan Molineaux - Founder, CEO, President & Director Emil Kuriakose - Chief Medical Officer Confere...

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the third quarter ended September 30, 2022. “Earlier in the fourt...

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company’s third quarter 2022 financial results will be released on Monday, November 14, 2022. Com...

Calithera Biosciences, Inc. ( NASDAQ: CALA ) added ~16% pre-market Monday after the oncology-focused biotech announced that the FDA issued the Fast Track designation for sapanisertib as a treatment for adults with a certain type of lung cancer. Specifically, the FDA ha...

SOUTH SAN FRANCISCO, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation for the company&#x...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The question of when to add risk to a portfolio is a difficult one to answer. A rush toward riskier equities after the pandemic-induced sell-off led to a surge in many stocks. Among the biggest winners were penny stocks who...

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will ...

Calithera Biosciences ( NASDAQ: CALA ) is trading ~8% higher after HC Wainwright upgrades rating to Buy to Neutral, with an $8 price target. HC Wainwright analyst Swayampakula Ramakant believes the company has sufficient cash to fund operations into Q2 of 202...